Business Wire

MA-NETSCOUT-SYSTEMS

21.9.2021 12:03:07 CEST | Business Wire | Press release

Share
Cybercriminal Attacks Accelerate Global Cybersecurity Crisis According to 1H2021 NETSCOUT Threat Intelligence Report

NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report that underscore the dramatic impact cyberattacks continue to have on private and public organizations and governments worldwide. In the first half of 2021, cybercriminals launched approximately 5.4 million Distributed Denial of Services (DDoS) attacks, increasing 11% over 1H2020 figures. Additionally, data projections from NETSCOUT's Active Level Threat Analysis System (ATLAS™) Security Engineering and Response Team (ASERT) point to 2021 as another record-setting year on track to surpass 11 million global DDoS attacks. ASERT expects this long tail of attacker innovation to last, fueling a growing cybersecurity crisis that will continue to impact public and private organizations.

In the wake of Colonial Pipeline, JBS, Harris Federation, Australian broadcaster Channel Nine, CNA Financial, and several other high-profile attacks, the impact of DDoS and other cybersecurity attacks has been felt worldwide. As a result, leading governments are introducing new programs and policies to defend against attacks, and policing organizations are initiating unprecedented collaborative efforts to address the crisis.

During 1H2021, cybercriminals weaponized and exploited seven newer reflection/amplification DDoS attack vectors putting organizations at greater risk. This attack vector explosion spurred an increase in multivector DDoS attacks with a record-setting 31 attack vectors deployed in a single attack against one organization.

Other key findings from the NETSCOUT 1H2021 Threat Intelligence Report include:

  • New adaptive DDoS attack techniques evade traditional defenses. By customizing their strategies, cybercriminals evolved their attack efforts to bypass cloud-based and on-premise static DDoS defenses to target commercial banks and credit card processors.
  • Connectivity supply chain increasingly under attack. Bad actors looking to cause the most collateral damage focused their efforts on vital internet components, including DNS servers, virtual private network (VPN) concentrators, services, and internet exchanges, disrupting essential gateways.
  • Cybercriminals add DDoS to their toolkit to launch triple extortion campaigns. Ransomware has become big business, with extortionists adding DDoS to their attack regimen to ratchet up the pressure on victims and add stress to security teams. Triple extortion combines file encryption, data theft, and DDoS attacks, increasing the possibility that cyber criminals receive payment.
  • The fastest DDoS attack recorded a 16.17% year-over-year increase. A Brazilian wireline broadband internet user launched the attack, which was likely related to online gaming. Using DNS reflection/amplification, TCP ACK flood, TCP RST flood, and TCP SYN/ACK reflection/amplification vectors, the sophisticated attack recorded 675 Mpps.
  • The largest DDoS attack, 1.5 Tbps, represented a year-over-year increase of 169%. ASERT data identified this attack against a German ISP, deploying a DNS reflection/amplification vector. This attack represents a dramatic increase in size over any attacks recorded in 1H2020.
  • Botnets contribute to major DDoS activity - Tracked botnet clusters and high-density attack-source zones worldwide showcased how malicious adversaries abused these botnets to participate in more than 2.8 million DDoS attacks. In addition, well-known IoT botnets Gafgyt and Mirai continue to pose a severe threat contributing to more than half of the total number of DDoS attacks.

"Cybercriminals are making front-page news launching an unprecedented number of DDoS attacks to take advantage of the pandemic's remote work shift by undermining vital components of the connectivity supply chain," stated Richard Hummel, threat intelligence lead, NETSCOUT. "Ransomware gangs added triple-extortion DDoS tactics to their repertoire. Simultaneously, the Fancy Lazarus DDoS extortion campaign kicked into high gear threatening organizations in multiple industries with a focus on ISPs and specifically their authoritative DNS servers."

NETSCOUT's Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data secured from NETSCOUT's Active Level Threat Analysis System (ATLAS™) coupled with NETSCOUT's ATLAS Security Engineering & Response Team (ASERT) insights.

The visibility and analysis represented in the Threat Intelligence Report and Omnis® Threat Horizon fuel the ATLAS Intelligence Feed used across NETSCOUT's Omnis security product portfolio to detect and block threat activity for enterprises and service providers worldwide.

For more information on NETSCOUT's semi-annual Threat Intelligence Report, please visit our interactive website . You can also find us on Facebook , LinkedIn, and Twitter for threat updates and the latest trends and insights.

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Our Omnis® cybersecurity advanced threat detection and response platform offers comprehensive network visibility, threat detection, highly contextual investigation, and automated mitigation at the network edge. NETSCOUT nGenius™ service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.

©2021 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/NETSCOUTinc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye